Tbsct-Fp
Tbsct-Fp · TBSCT-FP 10 mg/10mg · Powder · ABX advanced biochemical compounds Biochemische Forschungsreagenzien GmbH
NDC 71934-0022-03 · 5 VIAL, GLASS in 1 BOX / 10 mg in 1 VIAL, GLASS · BULK INGREDIENT · View full market →
Bulk ingredient — not a finished product
This NDC is a raw material (bulk ingredient) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.
Medicare Part D
This is a bulk ingredient, not a dispensable product — it is a raw material sold to manufacturers and compounders, so no plan prices it.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Tbsct-Fp (Powder)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| ABX advanced biochemical compounds Biochemische Forschungsreagenzien GmbH | TBSCT-FP 10 mg/10mg | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Tbsct-Fp — NDC 71934-0022-03," retrieved September 3, 2026, https://drugdashboards.com/drug/71934002203.
Free to cite with attribution — see how the data is put together.